AI In-Brief

Thailand News in Brief

Thai PBS World

Thailand and the world, every day

AI can make mistakes. Please double-check.

GPO to begin Phase 3 clinical trials of its COVID vaccine in December

23 Sept 06:23 Key points summarised by AI

Thailand's Government Pharmaceutical Organisation (GPO) aims to commence Phase 3 clinical trials for its HXP-GPOVac COVID-19 vaccine in December, following anticipated positive Phase 2 results.
The Phase 3 trials will evaluate the GPO vaccine's efficacy as a booster shot in volunteers previously inoculated with other COVID-19 vaccines like AstraZeneca and Pfizer.
If proven effective, the locally-developed GPO vaccine, supported by PATH and a US-based prototype, will seek registration with the Thai FDA for booster use.
Other Thai institutions, including Chulalongkorn University (mRNA vaccine trials restarting) and Baiya Phytopharm (plant-based vaccine in Phase 2), are also advancing their COVID vaccine candidates, all intended as boosters.

Yesterday 09:24 Key points summarised by AI

Thailand secured a US$200 million loan from the World Bank to significantly invest in clean energy and low-carbon urban development initiatives.
The program aims to drive clean energy funding and low-carbon growth, ensuring a just transition for small and medium-sized enterprises, workers, farmers, and local communities.
Channelled through the Export-Import Bank of Thailand, the loan will fund energy efficiency upgrades in public buildings and industrial areas, including rooftop solar installations and electrical system modernizations, reducing initial capital burdens via Energy Service Companies (ESCOs).